{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:23:38Z","timestamp":1790969018647,"version":"4.1.0"},"reference-count":59,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Continuous oral targeted therapies (OTT) represent a major economic burden on the Canadian healthcare system, due to their high cost and administration until disease progression\/toxicity. The recent introduction of venetoclax-based fixed-duration combination therapies has the potential to reduce such costs. This study aims to estimate the prevalence and the cost of CLL in Canada with the introduction of fixed OTT. Methods: A state transition Markov model was developed and included five health states: watchful waiting, first-line treatment, relapsed\/refractory treatment, and death. The number of CLL patients and total cost associated with CLL management in Canada for both continuous- and fixed-treatment-duration OTT were projected from 2020 to 2025. Costs included drug acquisition, follow-up\/monitoring, adverse event, and palliative care. Results: The CLL prevalence in Canada is projected to increase from 15,512 to 19,517 between 2020 and 2025. Annual costs were projected at C$880.7 and C$703.1 million in 2025, for continuous and fixed OTT scenarios, respectively. Correspondingly, fixed OTT would provide a total cost reduction of C$213.8 million (5.94%) from 2020 to 2025, compared to continuous OTT. Conclusions: Fixed OTT is expected to result in major reductions in cost burden over the 5-year projection, compared to continuous OTT.<\/jats:p>","DOI":"10.3390\/curroncol30050339","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T02:06:35Z","timestamp":1682388395000},"page":"4483-4498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0791-2518","authenticated-orcid":false,"given":"Jean","family":"Lachaine","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, University of Montreal, Montreal, QC H3T 1J4, Canada"},{"name":"PeriPharm Inc., Montreal, QC H2Y 2H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-1178","authenticated-orcid":false,"given":"Kimberly","family":"Guinan","sequence":"additional","affiliation":[{"name":"PeriPharm Inc., Montreal, QC H2Y 2H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Aw","sequence":"additional","affiliation":[{"name":"Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-8818","authenticated-orcid":false,"given":"Versha","family":"Banerji","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba Research Institute, Winnipeg, MB R3E 0V9, Canada"},{"name":"Departments of Internal Medicine and Biochemistry & Medical Genetics, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0W2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"Maisonneuve-Rosemont Hospital, Institut Universitaire H\u00e9mato-Oncologie Transplantation Cellulaire, Montreal University, Montreal, QC H1T 2M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[{"name":"Foothills Medical Centre, Calgary, AB T2N 2T9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"ref_1","unstructured":"Leukemia and Lymphoma Society of Canada (2020, October 01). Blood Cancer in Canada-Facts and Stats. Available online: https:\/\/www.llscanada.org\/disease-information\/facts-and-statistics#Leukemia."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3324\/haematol.2013.086066","article-title":"Chronic lymphocytic leukemia in young (\u226455 years) patients: A comprehensive analysis of prognostic factors and outcomes","volume":"99","author":"Parikh","year":"2014","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1200\/EDBK_159018","article-title":"Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?","volume":"35","author":"Brown","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_4","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH)-pCODR (2020, November 05). Provincial Funding Summary: Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (pCODR 10043). Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-provfund_ibrutinib_imbruvica-CLL.pdf."},{"key":"ref_5","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH)-pCODR (2020, November 07). Provincial Funding Summary: Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia\/Small Lymphocytic Leukemia (Previously Untreated) (pCODR 10085). Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-provfund_ibrutinib_imbruvica-cll-sll-preun.pdf."},{"key":"ref_6","unstructured":"(2019). Product Monograph Including Patient Medication Information: Calquence (Acalabrutinib Capsules), AstraZeneca Canada Inc."},{"key":"ref_7","unstructured":"Pan-Canadian Oncology Drug Review (pCODR) (2020, November 01). pCODR Expert Review Committee (pERC) Final Recommendation: Acalabrutinib (CALQUENCE). Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10211AcalabrutinibCLL_fnRec_REDACT_EC_Post17Nov2020_final.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-0881-4","article-title":"Revolution of Chronic Lymphocytic Leukemia Therapy: The Chemo-Free Treatment Paradigm","volume":"22","author":"Scheffold","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/curroncol28010037","article-title":"Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada","volume":"28","author":"Lachaine","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_12","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH)-pCODR (2020, November 07). Provincial Funding Summary: Venetoclax (Venclexta) in Combo Rituximab for Chronic Lymphocytic Leukemia (pCODR 10162). Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_provfund_10162_venetoclax_venclexta_and_rituximab.pdf."},{"key":"ref_13","unstructured":"Pan-Canadian Oncology Drug Review (pCODR) (2020, November 01). pCODR Expert Review Committee (pERC) Final Recommendation: Venetoclax (Venclexta) in Combination with Obinutuzumab. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10212VenetoclaxObinutuzumabCLL_fnRec_EC_Post17Nov2020_final.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","unstructured":"European Medicines Agency (EMA) (2021, May 01). Venclyxto-Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/venclyxto-epar-product-information_en.pdf."},{"key":"ref_17","unstructured":"Statistics Canada (2020, November 03). Number and Rates of New Cases of Primary Cancer, by Cancer Type, Age Group and Sex. Table: 13-10-0111-01. Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310011101&pickMembers%5B0%5D=2.1&pickMembers%5B1%5D=3.1&pickMembers%5B2%5D=4.51."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","unstructured":"Statistics Canada (2020, November 03). Life Expectancy and Other Elements of the Life table, Canada, All Provinces Except Prince Edward Island (Table: 13-10-0114-01). Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310011401&pickMembers%5B0%5D=1.1&pickMembers%5B1%5D=3.1&pickMembers%5B2%5D=4.3&cubeTimeFrame.startYear=2013+%2F+2015&cubeTimeFrame.endYear=2017+%2F+2019&referencePeriods=20130101%2C20170101."},{"key":"ref_22","unstructured":"Ministry of Health and Long Term Care Ontario Health Insurance Plan (2020, November 03). Schedule of Benefits for Laboratory Services, Available online: https:\/\/health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/physserv\/sob_master.pdf."},{"key":"ref_23","unstructured":"Ministry of Health and Long Term Care Ontario Health Insurance Plan (2020, November 03). Schedule of Benefits-Physician Services under the Health Insurance Act, Available online: https:\/\/health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/lab\/lab_mn2020.pdf."},{"key":"ref_24","unstructured":"Statistics Canada (2020, October 01). Average Usual Hours and Wages by Selected Characteristics, Monthly, Unadjusted for Seasonality (Table: 14-10-0320-02). Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1410032002."},{"key":"ref_25","unstructured":"Government of Canada (2020, October 03). Job Bank-Wage Report. Available online: https:\/\/www.jobbank.gc.ca\/wagereport\/location\/geo9219."},{"key":"ref_26","unstructured":"Ontario Ministry of Health and Long Term Care (2020, October 02). Ontario Care Costing Analysis Tool. Available online: https:\/\/hsimi.ca\/occp\/occpreports\/."},{"key":"ref_27","first-page":"S151","article-title":"Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: Final survival analaysis of CLL 11 study","volume":"215923","author":"Goede","year":"2018","journal-title":"EMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequentialtreatment with rituximab in symptomatic, untreated patients with B-cellchronic lymphocytic leukemia: Results from Cancer and LeukemiaGroup B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in Combination With Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00277-012-1660-6","article-title":"Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia","volume":"92","author":"Niederle","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kater, A.P., Kipps, T.J., Eichhorst, B., Hillmen, P., D\u2019Rozario, J., Owen, C., Assouline, S.E., Lamanna, N., Robak, T.J., and la Serna, J. (2020, December 05). Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed\/Refractory Chronic Lymphocytic Leukemia (R\/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). Available online: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136109.html.","DOI":"10.1182\/blood-2020-136109"},{"key":"ref_41","first-page":"2849","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: Updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: A Multicentre, Open-Label Phase 2 Trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","unstructured":"Alberta Health Services (2020, November 05). Clinical Practice Guideline LYHE0007-Chronic Lymphocytic Leukemia (Version 6). Available online: https:\/\/www.albertahealthservices.ca\/assets\/info\/hp\/cancer\/if-hp-cancer-guide-lyhe007-cll.pdf."},{"key":"ref_46","unstructured":"Cancer Care Ontario (2020, November 01). Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens."},{"key":"ref_47","unstructured":"IQVIA Delta PA (2020)."},{"key":"ref_48","unstructured":"Canadian Institute for Health Information (CIHI) (2020, November 01). Patient Cost Estimator. Available online: https:\/\/www.cihi.ca\/en\/patient-cost-estimator."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jval.2018.09.166","article-title":"PCN84-total cost of care and budget impact for patients with cll treated with venetoclax","volume":"21","author":"Cho","year":"2018","journal-title":"Value Health"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40273-020-00919-1","article-title":"Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States","volume":"38","author":"Cho","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-137034","article-title":"Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France","volume":"136","author":"Fang","year":"2020","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1182\/blood-2011-11-312421","article-title":"Risk categories and refractory CLL in the era of chemoimmunotherapy","volume":"119","author":"Zenz","year":"2012","journal-title":"Blood"},{"key":"ref_53","first-page":"Abstract EP722","article-title":"The Management and use of Healthcare Resources in Patients with Chronic Lymphocyctic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE) Across Canada: Interim Analysis","volume":"81","author":"Banerji","year":"2020","journal-title":"Eur. Hematol. Assoc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice","volume":"25","author":"Roeker","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.14540","article-title":"Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: Results from a multi-centre study","volume":"181","author":"Mato","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-020-00870-w","article-title":"Ibrutinib dose modifications in the management of CLL","volume":"13","author":"Pinotti","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.3747\/co.26.4957","article-title":"Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre","volume":"26","author":"Uminski","year":"2019","journal-title":"Curr. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/5\/339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:22:43Z","timestamp":1760124163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/5\/339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["curroncol30050339"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30050339","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]}}}